BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 28315927)

  • 21. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
    Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
    J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symptoms and endoscopic features at barrett's esophagus diagnosis: implications for neoplastic progression risk.
    Coleman HG; Bhat SK; Murray LJ; McManus DT; O'Neill OM; Gavin AT; Johnston BT
    Am J Gastroenterol; 2014 Apr; 109(4):527-34. PubMed ID: 24589668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Biomarkers for Human Papillomavirus With Survival Among Adults With Barrett High-grade Dysplasia and Esophageal Adenocarcinoma.
    Rajendra S; Sharma P; Gautam SD; Saxena M; Kapur A; Sharma P; Merrett N; Yang T; Santos LD; Pavey D; Sharaiha O; McKay O; Dixson H; Xuan W
    JAMA Netw Open; 2020 Feb; 3(2):e1921189. PubMed ID: 32058552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients.
    Younes M; Brown K; Lauwers GY; Ergun G; Meriano F; Schmulen AC; Barroso A; Ertan A
    Histopathology; 2017 Jul; 71(1):27-33. PubMed ID: 28226185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia.
    Khoshiwal AM; Frei NF; Pouw RE; ; Smolko C; Arora M; Siegel JJ; Duits LC; Critchley-Thorne RJ; Bergman JJGHM
    Gastroenterology; 2023 Nov; 165(5):1168-1179.e6. PubMed ID: 37657759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of low-grade dysplasia in Barrett's esophagus.
    Wani S
    Curr Opin Gastroenterol; 2012 Jul; 28(4):370-6. PubMed ID: 22508323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Screening Tests for Barrett's Esophagus.
    Codipilly DC; Iyer PG
    Curr Gastroenterol Rep; 2019 Jul; 21(9):42. PubMed ID: 31346777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.
    Huhta H; Helminen O; Lehenkari PP; Saarnio J; Karttunen TJ; Kauppila JH
    Oncotarget; 2016 Apr; 7(17):23658-67. PubMed ID: 27008696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma.
    Becker L; Huang Q; Mashimo H
    Dis Esophagus; 2010 Feb; 23(2):168-74. PubMed ID: 19549212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential application of p53 as an intermediate biomarker in Barrett's esophagus.
    Jones DR; Davidson AG; Summers CL; Murray GF; Quinlan DC
    Ann Thorac Surg; 1994 Mar; 57(3):598-603. PubMed ID: 8147627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions.
    Choy B; LaLonde A; Que J; Wu T; Zhou Z
    Hum Pathol; 2016 Nov; 57():126-135. PubMed ID: 27476776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved Progression Prediction in Barrett's Esophagus With Low-grade Dysplasia Using Specific Histologic Criteria.
    Ten Kate FJC; Nieboer D; Ten Kate FJW; Doukas M; Bruno MJ; Spaander MCW; Looijenga LHJ; Biermann K;
    Am J Surg Pathol; 2018 Jul; 42(7):918-926. PubMed ID: 29697438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High expression of Claudin-2 in esophageal carcinoma and precancerous lesions is significantly associated with the bile salt receptors VDR and TGR5.
    Abu-Farsakh S; Wu T; Lalonde A; Sun J; Zhou Z
    BMC Gastroenterol; 2017 Feb; 17(1):33. PubMed ID: 28212604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus.
    Wolf WA; Pasricha S; Cotton C; Li N; Triadafilopoulos G; Muthusamy VR; Chmielewski GW; Corbett FS; Camara DS; Lightdale CJ; Wolfsen H; Chang KJ; Overholt BF; Pruitt RE; Ertan A; Komanduri S; Infantolino A; Rothstein RI; Shaheen NJ
    Gastroenterology; 2015 Dec; 149(7):1752-1761.e1. PubMed ID: 26327132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.